Start-Ups in Biotechnology
This article was originally published in Start Up
Executive Summary
For start-ups in biotech, it's the worst and the best of times. On the one hand, new opportunities and new sources of financing. On the other, too many companies and cutthroat competition. Interviews with venture capitalist Lawrence Bock, Peter Drake,PhD, of Vector Securities, and Richard Dimarchi, PhD, vice president of research technology and proteins for Eli Lilly & Co., shed light on current trends.